Noxopharm Announces AU$26 Million Funding Facility
July 19, 2019 08:00 ET
|
Noxopharm, Ltd.
KEY HIGHLIGHTS AU$4,000,000 initial fundingEquity placement component of up to additional AU$22,000,000 in ordinary shares over 12 monthsFlexible funding package leading up to a proposed U.S....
Conference Hears of Positive Interim Data from LuPIN Trial
June 26, 2019 08:00 ET
|
Noxopharm, Ltd.
KEY HIGHLIGHTS LuPIN study enrolling heavily pre-treated men with progressive late-stage prostate cancer (mCRPC) Clinical data shows combining Veyonda® with radiopharmaceutical, 177Lu-PSMA-617, is...
Promising Data Leads to Expansion of LuPIN Trial
May 23, 2019 08:00 ET
|
Noxopharm, Ltd.
LuPIN trial to recruit additional 24 patients Additional patients to be treated with Veyonda® 1200 mgThe objective is to see whether the dose-response effect seen to date will lead to even greater...
LuPIN Trial Demonstrates High Rates of Response
May 20, 2019 08:00 ET
|
Noxopharm, Ltd.
Data published today describes positive interim results from the LuPIN trial Veyondaâ (NOX66) dose-finding study69% combined PSA response rate is higher than that observed in studies of 177Lu-PSMA-617...
DARRT Treatment Has Lasting Disease Control at Six Months
May 02, 2019 08:00 ET
|
Noxopharm, Ltd.
Long-lasting responses with Veyonda® + low-dose radiotherapy in late-stage prostate cancer High proportion of disease control following a single, short course of treatmentComplete resolution of pain...
Idronoxil Confirmed as Noxopharm’s New Immuno-Oncology Drug Candidate
April 16, 2019 08:00 ET
|
Noxopharm, Ltd.
New class of immuno-oncology drug identifiedActivator of NK cells and CD4+ immune cellsPotential to boost function of current immuno-oncology drugs. SYDNEY, Australia, April 16, 2019 (GLOBE...
Veyonda® Chemotherapy Enhancement Program to be Expanded
April 10, 2019 08:00 ET
|
Noxopharm, Ltd.
Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancersU.S. study to investigate Veyonda® + doxorubicin in sarcomasCEP-2 target start Q4...
Combination of Veyonda® + Radiotherapy Delivers Clinical Benefits In Noxopharm’s DARRT-1 Interim Results
February 06, 2019 08:00 ET
|
Noxopharm, Ltd.
Interim (12-week) DARRT-1 readout Combination Veyonda® + low-dose radiotherapy well toleratedPSA, pain and tumour responses at higher doses24-week readout to indicate longevity of response. SYDNEY,...
Principal Investigator Discusses LuPIN-1 Study
January 14, 2019 13:34 ET
|
Noxopharm, Ltd.
Lu-PIN-1 Study two-thirds enrolledStudy testing ability of Veyonda® to boost effect of Novartis experimental drugNoxopharm to initiate LuPIN-2 study. SYDNEY, Australia, Jan. 14, 2019 (GLOBE...
NOX Announces Positive Data from CEP-1 Study of Veyonda®
November 29, 2018 08:00 ET
|
Noxopharm, Ltd.
Final CEP-1 data confirm tolerability of Veyonda® alone and in combination with carboplatinHalt in progression of cancer growth in 50% of patients Study provides proof-of-concept for well-tolerated...